Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3577 in Type 2 Diabetes
NCT00868790Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-3577 in type 2 diabetes mellitus (T2DM) (14 arms), sponsored by Merck & Co. Primary endpoints: Weighted Mean Glucose at 4 weeks, Number of Participants With At Least One Adverse Event at 18 weeks and 1 more. Started Mar 2009; status: terminated.
02
Drugs
MK-3577
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00868790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868790.